PepGen seeks funds on the back of early-stage data in muscle wasting disease

PepGen posted positive data from an early-stage trial of its oligonucleotide for a rare muscle wasting condition Wednesday. It also announced a $100 million follow-on offering soon after. The Boston-based biotech' ...